Terms: = Kidney tumors AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Clinical Outcome
4 results:
1. Identifying Prognostic Biomarkers Related to m6A Modification and Immune Infiltration in Renal Cell Carcinoma.
Ye J; Li P; Zhang H; Wu Q; Yang D
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360294
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract] [Full Text] [Related]
3. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract] [Full Text] [Related]
4. Low-grade tubular-mucinous renal neoplasms: morphologic, immunohistochemical, and genetic features.
Rakozy C; Schmahl GE; Bogner S; Störkel S
Mod Pathol; 2002 Nov; 15(11):1162-71. PubMed ID: 12429795
[TBL] [Abstract] [Full Text] [Related]
